FDA Announces Joint Meeting of Pulmonary-Allergy Drugs and Drug Safety Committees

Summary

The US Food and Drug Administration (FDA) has scheduled a joint meeting of the Pulmonary-Allergy Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss various pharmaceutical proposals and address recent safety concerns.